AMRX Amneal Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of complex generic and branded pharmaceutical products focusing on high-barrier, high-value formulations
• • New product emphasis: Launch of five oncology biosimilars including Boncresa™ and Oziltus™ FDA-approved in Dec 2025, plus first complex inhalation aerosol generics from Ireland facility
• • Strategic shift: Expanded respiratory platform with injectable drug/device combos and long-acting injectables targeting hospital sector growth
• • Quantitative highlight: Pipeline includes 61 pending ANDAs, 43 in development with 95% non-oral solids, FDA approval of multiple key respiratory and biosimilar products in 2025
• • Noteworthy fact: First commercial approvals for products produced at new Ireland manufacturing facility in 2025, signifying geographic and complexity expansion

Risk Factors

• • Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754
• • Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text
• • Litigation and government investigations with uncertain outcomes; accruals based on low end of probable loss range
• • No specific named competitor or technology disruption risk disclosed in risk factors
• • Potential volatility in tax valuation allowance reversals impacting contingent TRA liabilities and related income statement charges

Management Discussion & Analysis

• • Net cash from operating activities $340.0M in 2025 vs $295.1M in 2024; 15.2% increase but lower YoY excluding $52.4M prior litigation settlement
• • Net cash used in investing activities $112.3M in 2025 vs $63.0M in 2024; 78.2% increase due to higher capex and property deposits
• • Net cash used in financing activities $31.5M in 2025 vs $211.8M in 2024; 85.1% decrease due to debt refinancing and related party note repayment
• • Goodwill allocated: Specialty $366.3M, Affordable Medicines $159.7M, AvKARE $69.5M; no goodwill impairment in 2025
• • Management identified critical accounting estimates in sales deductions, business combinations, goodwill impairment, income taxes, and contingencies

What are the latest AMRX SEC filings in 2026?

Amneal Pharmaceuticals, Inc. (AMRX) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AMRX file its most recent 10-K annual report?

Amneal Pharmaceuticals, Inc. (AMRX) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AMRX 10-Q quarterly reports?

Amneal Pharmaceuticals, Inc. (AMRX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every AMRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AMRX filed recently?

Amneal Pharmaceuticals, Inc. (AMRX)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AMRX insider trading activity (Form 4)?

SignalX aggregates every AMRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AMRX file with the SEC?

Amneal Pharmaceuticals, Inc. (AMRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AMRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Amneal Pharmaceuticals, Inc. (AMRX).

What is AMRX's SEC CIK number?

Amneal Pharmaceuticals, Inc. (AMRX)'s SEC CIK (Central Index Key) number is 1723128. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1723128 to look up all AMRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AMRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Amneal Pharmaceuticals, Inc. (AMRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.